More stories

  • in

    At last, China pulls the trigger on a bold stimulus package

    TWO GUT instincts have distinguished the macroeconomic policies of Xi Jinping, China’s ruler since 2012. He has disdained consumer handouts, which he thinks breed laziness. And he has refrained from bold economic stimulus, the kind of fiscal and monetary “bazooka” that China’s previous leaders fired in November 2008 during the global financial crisis. Both of Mr Xi’s convictions have been tested by China’s economic woes over the past year. And this week, shortly before the 75th anniversary of the People’s Republic of China, he appears to have set his qualms aside, permitting China’s most attention-grabbing stimulus since 2008. Chinese stocks posted their best week in 16 years; Hong Kong’s surged at a pace unseen since 1998. Some analysts have even used the b-word. More

  • in

    Why JPMorgan Chase is prepared to sue the U.S. government over Zelle scams

    JPMorgan disclosed that the Consumer Financial Protection Bureau could punish the lender for its role in Zelle, the giant peer-to-peer digital payments network.
    In response, JPMorgan issued a thinly veiled threat: “The firm is evaluating next steps, including litigation.”
    The prospect of a bank suing its regulator would’ve been unheard of in an earlier era, according to policy experts, but a combination of factors has created an environment where banks and their regulators have never been farther apart.
    Banks, airlines, pharmaceutical companies and energy firms have found ways to undermine the power of federal agencies, according to legal experts.

    JPMorgan Chase CEO and Chairman Jamie Dimon gestures as he speaks during the U.S. Senate Banking, Housing and Urban Affairs Committee oversight hearing on Wall Street firms, on Capitol Hill in Washington, D.C., on Dec. 6, 2023.
    Evelyn Hockstein | Reuters

    Buried in a roughly 200-page quarterly filing from JPMorgan Chase last month were eight words that underscore how contentious the bank’s relationship with the government has become.
    The lender disclosed that the Consumer Financial Protection Bureau could punish JPMorgan for its role in Zelle, the giant peer-to-peer digital payments network. The bank is accused of failing to kick criminal accounts off its platform and failing to compensate some scam victims, according to people who declined to be identified speaking about an ongoing investigation.

    In response, JPMorgan issued a thinly veiled threat: “The firm is evaluating next steps, including litigation.”
    The prospect of a bank suing its regulator would’ve been unheard of in an earlier era, according to policy experts, mostly because corporations used to fear provoking their overseers. That was especially the case for the American banking industry, which needed hundreds of billions of dollars in taxpayer bailouts to survive after irresponsible lending and trading activities caused the 2008 financial crisis, those experts say.
    But a combination of factors in the intervening years has created an environment where banks and their regulators have never been farther apart.
    Trade groups say that in the aftermath of the financial crisis, banks became easy targets for populist attacks from Democrat-led regulatory agencies. Those on the side of regulators point out that banks and their lobbyists increasingly lean on courts in Republican-dominated districts to fend off reform and protect billions of dollars in fees at the expense of consumers.
    “If you go back 15 or 20 years, the view was it’s not particularly smart to antagonize your regulator, that litigating all this stuff is just kicking the hornet’s nest,” said Tobin Marcus, head of U.S. policy at Wolfe Research.

    “The disparity between how ambitious [President Joe] Biden’s regulators have been and how conservative the courts are, at least a subset of the courts, is historically wide,” Marcus said. “That’s created so many opportunities for successful industry litigation against regulatory proposals.”

    Assault on fees

    Those forces collided this year, which started out as one of the most consequential for bank regulation since the post-2008 reforms that curbed Wall Street risk-taking, introduced annual stress tests and created the industry’s lead antagonist, the CFPB.
    In the final months of the Biden administration, efforts from a half-dozen government agencies were meant to slash fees on credit card late payments, debit transactions and overdrafts, among other proposals. The industry’s biggest threat was the Basel Endgame, a sweeping plan to force big banks to hold tens of billions of dollars more in capital for activities like trading and lending.
    “The industry is facing an onslaught of regulatory and potential legislative change,” Marianne Lake, head of JPMorgan’s consumer bank, warned investors in May.

    JPMorgan’s disclosure about the CFPB probe into Zelle comes after years of grilling by Democrat lawmakers over financial crimes on the platform. Zelle was launched in 2017 by a bank-owned firm called Early Warning Services in response to the threat from peer-to-peer networks including PayPal.
    The vast majority of Zelle activity is uneventful; of the $806 billion that flowed across the network last year, only $166 million in transactions was disputed as fraud by customers of JPMorgan, Bank of America and Wells Fargo, the three biggest players on the platform.
    But the three banks collectively reimbursed just 38% of those claims, according to a July Senate report that looked at disputed unauthorized transactions.
    Banks are typically on the hook to reimburse fraudulent Zelle payments that the customer didn’t give permission for, but usually don’t refund losses if the customer is duped into authorizing the payment by a scammer, according to the Electronic Fund Transfer Act.
    A JPMorgan payments executive told lawmakers in July that the bank actually reimburses 100% of unauthorized transactions; the discrepancy in the Senate report’s findings is because bank personnel often determine that customers have authorized the transactions.
    Amid the scrutiny, the bank began warning Zelle users on the Chase app to “Stay safe from scams” and added disclosures that customers won’t likely be refunded for bogus transactions.
    JPMorgan declined to comment for this article.

    Dimon in front

    The company, which has grown to become the largest and most profitable American bank in history under CEO Jamie Dimon, is at the fore of several other skirmishes with regulators.
    Thanks to his reputation guiding JPMorgan through the 2008 crisis and last year’s regional banking upheaval, Dimon may be one of few CEOs with the standing to openly criticize regulators. That was highlighted this year when Dimon led a campaign, both public and behind closed doors, to weaken the Basel proposal.
    In May, at JPMorgan’s investor day, Dimon’s deputies made the case that Basel and other regulations would end up harming consumers instead of protecting them.
    The cumulative effect of pending regulation would boost the cost of mortgages by at least $500 a year and credit card rates by 2%; it would also force banks to charge two-thirds of consumers for checking accounts, according to JPMorgan.
    The message: banks won’t just eat the extra costs from regulation, but instead pass them on to consumers.
    While all of these battles are ongoing, the financial industry has racked up several victories so far.
    Some contend the threat of litigation helped convince the Federal Reserve to offer a new Basel Endgame proposal this month that roughly cuts in half the extra capital that the largest institutions would be forced to hold, among other industry-friendly changes.
    It’s not even clear if the watered-down version of the proposal, a long-in-the-making response to the 2008 crisis, will ever be implemented because it won’t be finalized until well after U.S. elections.
    If Republican candidate Donald Trump wins, the rules might be further weakened or killed outright, and even under a Kamala Harris administration, the industry could fight the regulation in court.
    That’s been banks’ approach to the CFPB credit card rule, which aimed to cap late fees at $8 per incident and was set to go into effect in May.
    A last-ditch effort from the U.S. Chamber of Commerce and bank trade groups successfully delayed its implementation when Judge Mark Pittman of the Northern District of Texas sided with the industry, granting a freeze of the rule.

    ‘Venue shopping’

    A key playbook for banks has been to file cases in conservative jurisdictions where they are likely to prevail, according to Lori Yue, a Columbia Business School associate professor who has studied the interplay between corporations and the judicial system.
    The Northern District of Texas feeds into the 5th Circuit Court of Appeals, which is “well-known for its friendliness to industry lawsuits against regulators,” Yue said.
    “Venue-shopping like this has become well-established corporate strategy,” Yue said. “The financial industry has been particularly active this year in suing regulators.”
    Since 2017, nearly two-thirds of the lawsuits filed by the U.S. Chamber of Commerce challenging federal regulations have been in courts under the 5th Circuit, according to an analysis by Accountable US.
    Industries dominated by a few large players — from banks to airlines, pharmaceutical companies and energy firms — tend to have well-funded trade organizations that are more likely to resist regulators, Yue added.
    The polarized environment, where weakened federal agencies are undermined by conservative courts, ultimately preserves the advantages of the largest corporations, according to Brian Graham, co-founder of bank consulting firm Klaros.
    “It’s really bad in the long run, because it locks in place whatever the regulations have been, while the reality is that the world is changing,” Graham said. “It’s what happens when you can’t adopt new regulations because you’re terrified that you’ll get sued.”
    — With data visualizations by CNBC’s Gabriel Cortes.

    Don’t miss these insights from CNBC PRO More

  • in

    OpenAI CFO tells investors funding round should close by next week despite executive departures

    In an email to OpenAI’s investors, CFO Sarah Friar said the company still has a “talented leadership bench” following key departures this week.
    Friar also says its current funding round, which sources say values OpenAI at $150 billion, was oversubscribed and set to close next week.
    “Collectively, we remain laser-focused on bringing AI to everyone and building sustainable revenue models that fuel our operations and deliver value to our investors and employees,” Friar wrote.

    OpenAI’s Sora AI tool allows users to create AI-generated videos from text-based inputs.
    Costfoto | Nurphoto | Getty Images

    OpenAI CFO Sarah Friar is looking to reassure its investors that the richly valued artificial intelligence startup is still in a strong position and is poised to close a big funding round soon, despite losing top talent this week.
    In an email to OpenAI’s investors seen by CNBC, Friar addressed the departure of Chief Technology Officer Mira Murati, who announced her exit on Wednesday. Later that day, Sam Altman said two top research executives, Bob McGrew and Barret Zoph, were also leaving.

    “I wanted to personally reach out following the news of Mira’s departure from OpenAI,” Friar wrote in the letter, which was viewed by CNBC. “While leadership changes are never easy, I want to ensure you have the full context.”
    Friar added that, “We are incredibly proud of everything she’s helped build,” and said the San Francisco-based company still has a “talented leadership bench” to compete.
    OpenAI, which is backed by Microsoft and recently partnered with Apple on its AI for iPhones, is in the midst of closing a $6.5 billion funding round, which should value the company at roughly $150 billion, according to sources familiar with the matter. Thrive Capital is leading the round, and plans to invest $1 billion, according to sources.
    Friar said in the email that the funding round was oversubscribed and would close by next week. She said the team plans to host a series of calls with investors to introduce the group to key leaders from product and research teams.
    “Collectively, we remain laser-focused on bringing AI to everyone and building sustainable revenue models that fuel our operations and deliver value to our investors and employees,” Friar wrote. The company is “excited for you to be with us as we enter our next chapter,” she wrote.

    OpenAI declined to comment on the email.
    Murati’s departure comes after 6½ years at the company. She briefly served as interim CEO last year after the board of directors abruptly fired Altman. When Altman was quickly reinstated, Murati returned to the role of CTO.

    Sarah Friar has been named OpenAI CFO
    Anjali Sundaram | CNBC

    The company was already dealing with the loss of key executives. Co-founder John Schulman and safety chief Jan Leike left to join rival Anthropic. Co-founder Ilya Sutskever departed to start another AI company, while another founder, Greg Brockman, is on a leave of absence.
    Friar said Mark Chen will step into the role of of senior vice president of research, and leaders like Kevin Weil, who joined from Meta, and Srinivas Narayanan are the “right people to keep pushing the boundaries of innovation.”
    Friar was formerly CEO of Nextdoor, and before that CFO at Block, formerly Square.
    Also on Thursday, at an all-hands meeting, Altman denied that there are plans for him to receive a “giant equity stake” in the company, calling reports of such a development “just not true,” according to a person who was in attendance.
    Altman and Friar both said at the meeting, conducted by video, that investors have raised concerns about Altman not having equity in the company that he co-founded almost nine years ago, said the person, who asked not to be named because the gathering was only for employees.

    Don’t miss these insights from CNBC PRO More

  • in

    China optimism is surging. Why some investors are cautious

    China’s latest policy signals have a bigger impact on sentiment than resolving deeper issues such as real estate, analysts said.
    “The ‘shock and awe’ strategy could be meant to jumpstart the markets and boost confidence,” said Ting Lu, chief China economist at Nomura, but eventually it is still necessary to introduce well thought out policies to address many of the “deep-rooted problems.”
    “China’s policy moves to lower interest rates have not helped improve confidence among consumers who are fearful of borrowing in the first place,” Paul Christopher, head of global investment strategy at Wells Fargo Investment Institute, said in an email.

    A shareholder at a securities hall in Hangzhou, the capital of Zhejiang province in east China, on Sept. 24, 2024.
    Cfoto | Future Publishing | Getty Images

    BEIJING — China’s latest policy signals have a bigger impact on sentiment than resolving deeper issues such as real estate, analysts said.
    The Shanghai Composite rallied Thursday to close at a three-month high after state media reported Chinese President Xi Jinping led a Politburo meeting on the economy that morning.

    The unexpected high-level gathering called for halting the property market decline, and strengthening fiscal and monetary policy. It provided few specifics, while affirming central bank rate cuts announced earlier in the week.
    Markets should value how Beijing is recognizing the severity of the economic situation, and how its piecemeal approach so far hasn’t worked, Ting Lu, chief China economist at Nomura, said in a report Friday.
    “The ‘shock and awe’ strategy could be meant to jumpstart the markets and boost confidence,” Lu said, but eventually it is still necessary to introduce well thought out policies to address many of the “deep-rooted problems.”

    Growth in the world’s second-largest economy has slowed, dragged down by the real estate slump. Retail sales have risen by barely more than 2% in recent months, and industrial profits have barely grown for the first eight months of the year. Exports are one of the few bright spots.
    Nomura’s Lu said policymakers in particular need to stabilize property since it is in its fourth year of contraction. He estimated the impact of additional stimulus wouldn’t exceed 3% of China’s annual GDP.

    “Markets should place more emphasis on the specifics of the stimulus,” Lu said. “If not designed well, a stimulus program in a haste, even if seemingly large, could have a slow and limited impact on growth.”
    The People’s Bank of China this week cut major interest rates, and announced plans to lower rates for existing mortgage holders. The Ministry of Finance has yet to release major policies, despite reports of such plans.

    Questions about scale

    For some investment institutions, that’s still not enough to move the needle on their China outlook.
    “China’s policy moves to lower interest rates have not helped improve confidence among consumers who are fearful of borrowing in the first place,” Paul Christopher, head of global investment strategy at Wells Fargo Investment Institute, said in an email.
    “We would be selling emerging market equities at this point,” he said, “as we have little confidence in Beijing’s willingness to extend the large stimulus that is needed.”
    Christopher added that Thursday’s “announcement of coming fiscal stimulus is welcome, but it remains to be seen if China’s government is willing to take the steps necessary to reverse the psychological damage to household and private business sentiment.”
    The Chinese government has cracked down on real estate developers, after-school tutoring businesses and the gaming industry in recent years. Policymakers have since eased their stance, but business and consumer confidence has yet to recover.
    China’s latest interest rate cuts follow the U.S. Federal Reserve’s shift last week to easier monetary policy. U.S rate cuts theoretically give China’s central bank more room to reduce already-low domestic rates.
    A survey in September of more than 1,200 companies in China by the U.S.-based China Beige Book found that corporate borrowing declined, despite historic lows in the costs to do so.
    “One can certainly hope for a wealth effect from stocks and property, but stocks will be temporary and the wealth decline from property is overwhelming compared to any relief,” Shehzad Qazi, chief operating officer at the China Beige Book, a U.S.-based research firm, said in a note Thursday.
    He expects retail sales could pick up slightly in the next four to six months.
    Qazi also expects the latest rally in Chinese stocks to continue into the last three months of the year. But cautioned that policies announced this week for driving more capital into the stock market “are not yet operational, and some may never be.”

    Sentiment change

    Those caveats haven’t discouraged investors from piling into beaten-down Chinese stocks. The CSI 300 stock index climbed Friday, on pace for its best week since 2008. It could rise another 10% in the near term, Laura Wang, chief China equity strategist at Morgan Stanley, told CNBC’s “Street Signs Asia.”
    The sentiment shift has spread globally.
    “I thought that what the Fed did last week would lead to China easing, and I didn’t know that they were going to bring out the big guns like they did,” U.S. billionaire hedge fund founder David Tepper told CNBC’s “Squawk Box” on Thursday. “And I think there’s a whole shift.”
    Tepper said he bought more Chinese stocks this week.
    An important takeaway from Thursday’s high-level government meeting was the support for capital markets, in contrast to a more negative perception in China on the financial industry in recent years, said Bruce Liu, CEO of Esoterica Capital, an asset manager.
    “Hopefully this meeting is going to correct this misperception,” he said. “For China to keep growing in a healthy way, [they] really need a well-functioning capital market.”
    “I don’t think they sent any different messages,” Liu said. “It’s just [that] they emphasize it with detailed action plans. That made a difference.” More

  • in

    FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades

    The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. 
    The company expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October.
    Cobenfy will cost $1,850 for a month’s supply or $22,500 annually before insurance and other rebates, according to Bristol Myers Squibb executives.

    Bristol Myers Squibb’s Cobenfy drug
    Courtesy: Bristol Myers Squibb

    The Food and Drug Administration on Thursday approved Bristol Myers Squibb’s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. 
    Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient’s everyday life, making it difficult to go to school or work, socialize and complete other daily activities. Most people are diagnosed in their late teens to early 30s.

    Bristol Myers Squibb expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October, executives told CNBC. The drug is a badly needed new option for the nearly 3 million adults in the U.S. living with schizophrenia, some medical experts say.
    Only 1.6 million of those patients are treated for the condition, and 75% of them stop taking existing medications in the first 18 months because they struggle to find treatments that are effective or easy for them to tolerate, according to the drugmaker. 
    Cobenfy could also be a huge long-term sales opportunity for Bristol Myers Squibb, which faces pressure to offset the potential loss of revenue from top-selling treatments that will see their patents expire. The drug comes from the company’s whopping $14 billion acquisition of biotech company Karuna Therapeutics at the end of last year. 
    In a July research note, Guggenheim analysts said they view Cobenfy as a “longer-term multi-billion dollar opportunity” for the company. But they said the drug will likely have a slow launch, so it may not meaningfully contribute to Bristol Myers Squibb’s top line in 2024 and 2025. 
    “I think there’s potentially a really transformational moment in how we treat and talk about schizophrenia. And what you have is, unfortunately, an often disadvantaged population that doesn’t get the attention they deserve from a research and health-care perspective,” Andrew Miller, founder and former president of research and development of Karuna Therapeutics and now an advisor to Bristol Myers Squibb, told CNBC.

    “I think the most important moment is going to be five or 10 years from now, when we look back and say we’ve actually made a difference,” he continued. “We’ve helped people, we’ve improved outcomes, we’ve provided caregivers and physicians with another tool that they can use.”

    Dado Ruvic | Reuters

    Cobenfy will cost $1,850 for a month’s supply or $22,500 annually before insurance and other rebates, Bristol Myers Squibb executives said.
    They said that pricing is in line with existing branded oral schizophrenia treatments and that they expect most patients, particularly those enrolled in Medicare and Medicaid plans, to have minimal out-of-pocket costs for the drug. Around 80% of patients living with the condition are covered by government insurance, according to Bristol Myers Squibb.
    The company intends to launch a program aimed at helping patients afford Cobenfy, executives added. 
    It’s still unclear how much that program will increase access for people without insurance.
    Cobenfy will have to compete with some existing schizophrenia drugs – called antipsychotic treatments – with lower list prices, particularly generic copycats of branded treatments. For example, patients without insurance can get the generic version of an antipsychotic treatment called Abilify for as little as $16 for 30 once-daily tablets with free coupons from GoodRx.
    Existing schizophrenia drugs work by directly blocking the dopamine receptors in the brain to generally improve symptoms in patients. 
    But they come with a long list of serious potential side effects that can cause patients to stop treatment, including weight gain, excessive fatigue and involuntary, uncontrollable movements. Roughly a third of people with schizophrenia are also resistant to conventional antipsychotic treatments, according to WebMD.
    Cobenfy is the first treatment approved from a new class of drugs that do not directly block dopamine to improve symptoms of schizophrenia, Dr. Samit Hirawat, Bristol Myers Squibb’s chief medical officer, told CNBC. 
    He said one part of Cobenfy is a drug called xanomeline, which activates certain so-called muscarinic receptors in the brain to decrease dopamine activity without causing the side effects associated with antipsychotics. The second part of Cobenfy is called trospium, which reduces the gastrointestinal side effects linked to xanomeline, such as nausea, vomiting, diarrhea and constipation. 
    “The majority of these patients have already cycled through one or two of these products,” Adam Lenkowsky, Bristol Myers Squibb’s chief commercialization officer, told CNBC. “So the enthusiasm that we’re hearing from physicians is the opportunity to have a patient go onto treatment without seeing the side effects but also getting unprecedented like efficacy.” 

    More CNBC health coverage

    Lenkowsky said the company expects Cobenfy to eventually become the standard treatment for schizophrenia as physicians learn more about the drug and get more comfortable with prescribing it to patients. 
    But the price could limit use of the drug to patients who have already tried and failed with other existing treatments, said Nina Vadiei, clinical associate professor of pharmacotherapy and translational sciences at the University of Texas at Austin College of Pharmacy.
    “If it were up to me, I wouldn’t necessarily say we have to try X number of antipsychotics first. But I know from experience in a hospital setting that that is probably what’s going to have to happen because of cost, mainly,” said Vadiei, a clinical psychiatric pharmacist who sees patients with schizophrenia at San Antonio State Hospital.”

    Trial results and upcoming research

    The approval was based on data from three clinical trials comparing Cobenfy to a placebo, as well as two longer-term studies that examined how safe and tolerable the drug is for up to one year. Cobenfy met the main goal of the three trials, significantly decreasing symptoms of schizophrenia compared with a placebo, according to Bristol Myers Squibb. 
    In the studies, Cobenfy mostly led to mild to moderate side effects, which were mainly gastrointestinal and dissipated over time, Miller said.
    Bristol Myers Squibb said Thursday’s approval for schizophrenia may only be the beginning for Cobenfy.
    For example, the company has ongoing late-stage clinical trials examining Cobenfy’s potential in treating Alzheimer’s disease patients with psychosis. Bristol Myers Squibb said it expects to release data from those studies in 2026. 
    The company also plans to study Cobenfy’s potential to treat bipolar mania and irritability associated with autism. 
    “When we think about Cobenfy, we think about it as multiple indications packed in one product … because we are really developing the drug not only for schizophrenia but six other indications,” Hirawat said, referring to other potential uses for the drug. 
    — CNBC’s Angelica Peebles contributed to this report.

    Don’t miss these insights from CNBC PRO More

  • in

    Trademark dispute emerges over Tiger Woods’ new logo

    Tigeraire, a company that makes cooling products for athletes, said Sun Day Red and Tiger Woods have “unlawfully hijacked” Tigeraire’s design into their own branding.
    The dispute will bring the trademark application that Woods filed for his new logo to a halt.
    Sun Day Red pays homage to the fact that Woods always wears red on Sundays and the logo is a tribute to the 15 majors he’s won over the course of his career.

    Tiger Woods speaks during the launch of Tiger Woods and TaylorMade Golf’s new apparel and footwear brand “Sun Day Red” at Palisades Village on February 12, 2024 in Pacific Palisades, California.
    Kevork Djansezian | Getty Images Sport | Getty Images

    Tiger Woods’ new logo for his Sun Day Red golf apparel line is facing a trademark dispute.
    Tigeraire, a company that makes cooling products for athletes, has filed a notice of opposition with the U.S. Patent and Trademark Office, alleging that Sun Day Red and Tiger Woods have “unlawfully hijacked” Tigeraire’s design into their own branding.

    Arrows pointing outwards

    Applicant’s Marks and the Registered Mark.
    U.S. Patent and Trademark Office

    “The actions of SDR, TaylorMade and Tiger Woods blatantly ignore Tigeraire’s long-standing protected mark, brand and identity, violate federal and state intellectual property law, and disregard the consumer confusion their actions create. SDR’s application should be denied,” the court filing said.
    TaylorMade Golf, the company behind Sun Day Red, told CNBC, “We have full confidence in the securitization of our trademarks.”
    Sun Day Red was launched in May, following Woods’ 27-year partnership with Nike.
    The brand pays homage to the fact that Woods always wears red on Sundays and the logo is a tribute to the 15 majors he’s won over the course of his career, Woods said previously.

    A detail of hats and a club cover during the launch of Tiger Woods and TaylorMade Golf’s new apparel and footwear brand “Sun Day Red” at Palisades Village on February 12, 2024 in Pacific Palisades, California. 
    Kevork Djansezian | Getty Images Sport | Getty Images

    “Sun Day Red continues to penetrate the North American marketplace,” TaylorMade CEO David Abeles said. “Our products have been extremely well received.”

    A spokesman for Woods declined to comment on the matter.
    Woods and the Sun Day Red team will have 40 days to file an answer on the notice.
    The opposition proceeding will bring the trademark application that Woods filed for his new logo to a halt, Josh Gerben, a trademark attorney, told CNBC. It is unlikely to affect future production of the line, though, he said.
    “They now likely give themselves an opportunity to negotiate with Tiger and TaylorMade to see if there’s a resolution that might be had,” Gerben said.
    He expects the case to settle before it gets close to a trial.
    “By filing this opposition, the portable fan company really basically gets them a seat at the table to negotiate,” he said. “Because in order for Tiger and TaylorMade to get this trademark registered there, you’re gonna have to win this case.” More

  • in

    Wealthy investors support Harris over Trump, new survey says

    The majority of investors with at least $1 million of investible assets plan to vote for Vice President Kamala Harris, according to a UBS survey.
    However, the millionaire investors gave former President Donald Trump a better grade on the economy.

    Vice President and Democratic presidential candidate Kamala Harris speaks at the Philip Chosky Theatre during a campaign event in Pittsburgh, Pennsylvania, on September 25, 2024. 
    Jim Watson | AFP | Getty Images

    A majority of millionaire investors said they plan to vote for Vice President Kamala Harris in November, even though they give former President Donald Trump a better grade on the economy, according to new survey.
    According to a UBS survey of investors with at least $1 million of investible assets, 57% plan to vote for Harris and 43% plan to vote for Trump.

    Harris wins 91% of Democratic millionaires surveyed, 12% of Republicans and 60% of independents. Trump wins 88% of Republican millionaires, 9% of Democrats and 40% of independents.
    Like many voters, millionaire investors rated the economy as their No. 1 issue. Fully 84% said the economy is the top issue in the election, followed by Social Security (71%), then taxes (69%) and immigration.

    Get Inside Wealth directly to your inbox

    While they support Harris more broadly, the investors who were surveyed give Trump slightly higher marks on the economy and taxes. When asked “who is better equipped to address the economy,” 51% said Trump and 49% said Harris. Trump also edged out Harris on taxes, at 52% to 48%.
    Trump has proposed extending the 2017 tax cuts entirely, while Harris wants them to apply only to those making less than $400,000. She has also proposed higher taxes on the wealthy and corporations.
    Millionaire investors give Harris better grades on Social Security and health care.

    Whoever wins, however, millionaire investors are bullish on the economy and markets. A majority (55%) said they are highly confident about the economy, up from 43% during the same period in the 2020 election cycle (which was during the Covid-19 pandemic). Three-quarters of investors are also “highly optimistic” about their portfolio returns in the next six months.
    More than three-quarters of wealthy investors are also planning to make changes to their portfolios based on the election results. If Trump wins, they said defense and energy stocks look attractive, but if Harris wins, they said health-care, sustainable investing and tech names look best, according to the survey.
    The survey polled 971 investors with at least $1 million in investible assets between Aug. 13 and Aug. 19.

    Don’t miss these insights from CNBC PRO More

  • in

    Nuggets, Avalanche launch streaming service, with some games aired on local broadcast stations

    Local fans of the NBA’s Denver Nuggets and the NHL’s Colorado Avalanche will have a couple more ways to watch their teams’ games this season.
    Twenty of each team’s games will be aired via local broadcast stations owned by Tegna.
    All of the teams’ games that are not exclusive to a national network will be available on a new streaming service, Altitude+, for $19.95 a month.

    Nikola Jokic, #15 of the Denver Nuggets, shoots the ball against Bones Hyland, #5, and Norman Powell, #24, of the Los Angeles Clippers during the second half of a preseason game at Crypto.com Arena in Los Angeles on October 19, 2023.
    Kevork Djansezian | Getty Images

    Local fans of the NBA’s Denver Nuggets and the NHL’s Colorado Avalanche will have some new ways to watch their teams’ games this season.
    Kroenke Sports & Entertainment — Stan Kroenke’s company that owns several professional sports franchises including Denver’s NBA and NHL teams along with their regional sports network, Altitude — is partnering with broadcast station owner Tegna to offer a chunk of Avalanche and Nuggets games this season. It’s also launching a direct-to-consumer streaming service.

    The local broadcast partnership and new streaming service is part of a growing trend, especially among NBA and NHL teams, which are searching for more ways to offer games to fans who have turned away from the traditional pay TV bundle.
    Beginning this season, there will be 20 Nuggets and 20 Avalanche games on Tegna’s free local over-the-air broadcasts, 9NEWS and My20.
    Kroenke Sports & Entertainment is also launching the direct-to-consumer streaming service, Altitude+, in October. The platform will give fans in the Denver media market access to all Avalanche and Nuggets games for $19.95 a month.
    The NHL season begins on Oct. 4 when the New Jersey Devils and Buffalo Sabres play in Prague. The season in North America begins on Oct. 8. The NBA season begins on Oct. 22.
    While both teams’ local games are aired on Altitude Sports, the regional sports network is only available to fans in Denver on DirecTV and Fubo TV. It’s also available on Charter Communications’ Spectrum in some parts of its nine-state territory.

    However, Altitude hasn’t been available to Comcast and Dish pay TV customers since 2019, leaving a big hole in the Denver market. The availability on Tegna’s broadcast stations and the introduction of the streaming service may solve problems for fans in the market.
    “It certainly played a role. But what we’re really focused on is trying to get maximum exposure for our two great teams,” Steve Smith, president of Kroenke Sports & Entertainment’s KSE Media Ventures, said in an interview with CNBC. “And we think this deal really gives people the opportunity to do it however they want.”
    Altitude Sports sued Comcast in 2019 after the two sides could not reach a distribution agreement, leading to a so-called blackout for Comcast’s customers. The two sides settled in March 2023, but notably the settlement did not include a restoration of Altitude Sports on Comcast.
    The Bally Sports regional sports networks owned by Diamond Sports, which is under bankruptcy protection, went dark for Comcast customers earlier this year. However, the two sides reached an agreement in July.
    In the wake of Diamond Sports’ bankruptcy, numerous teams have parted ways with their regional sports networks, opting for deals with broadcasters and launching streaming services.
    Most recently, the NHL’s Dallas Stars and Anaheim Ducks exited Bally Sports. Stars games will be available on streaming service Victory+ this season, and the local Ducks games will be available via Victory+ and a local over-the-air broadcast. The streaming option for both is free.
    Meanwhile, the NBA’s Dallas Mavericks and New Orleans Pelicans have both turned to local over-the-air broadcasters instead of Bally Sports for all their games this season. This followed both teams reaching agreements similar to the Nuggets and Avalanche’s deal with Tegna. Before offering all games through broadcasters, the Pelicans had aired 10 of their matchups on Gray’s stations, while the Mavericks offered 13 games in the latter part of last season on Tegna’s stations.
    Regional sports networks are also increasingly offering streaming options.
    The YES Network, which airs MLB’s New York Yankees, and MSG Networks, which offers the NBA’s New York Knicks and NHL’s New York Rangers, among others, are also debuting a streaming option through a joint venture this fall.
    The pricing of regional sports networks’ streaming options reflects that they must be careful not to further disrupt the pay TV model and breach contracts with distributors. These pay TV contracts help support the billions of dollars in fees that the networks pay professional sports leagues to air their games.
    Disclosure: Comcast is the parent company of NBCUniversal and CNBC.

    Don’t miss these insights from CNBC PRO More